Trimodality Treatment and Selective Organ Preservation for Bladder Cancer
- 10 December 2006
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (35), 5536-5544
- https://doi.org/10.1200/jco.2006.07.6729
Abstract
Standard treatment for muscle-invasive bladder cancer is cystectomy. Trimodality treatment, including transurethral resection of the bladder tumor (TURBT), radiation therapy and chemotherapy, has been shown to produce survival rates comparable to those of cystectomy. With these programs, cystectomy has been reserved for patients with incomplete response or local relapse. During the past 15 years, organ preservation by trimodality treatment has been investigated in prospective series from single centers and cooperative groups, with more than 1,000 patients included. Five-year overall survival rates in the range of 50% to 60% have been reported, and approximately three quarters of the surviving patients maintained their bladder. Clinical criteria helpful in determining ideal patients for bladder preservation include early tumor stage (including high-risk T1 disease), a visibly complete TURBT, and absence of ureteral obstruction. Close coordination among all disciplines is required to achieve optimal results. Future investigations will focus on (1) optimizing radiation techniques and incorporating more effective systemic chemotherapy, and (2) the proper selection of patients based on molecular makers.Keywords
This publication has 81 references indexed in Scilit:
- Radiochemotherapy After Transurethral Resection for High-Risk T1 Bladder Cancer: An Alternative to Intravesical Therapy or Early Cystectomy?Journal of Clinical Oncology, 2006
- Phase II study of radiochemotherapy with vinblastine in invasive bladder cancerRadiotherapy and Oncology, 2005
- Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapyCancer, 2004
- p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined‐modality approachCancer, 2004
- CYSTECTOMY FOR BLADDER CANCER: A CONTEMPORARY SERIESJournal of Urology, 2001
- A PHASE I/II TRIAL OF TRANSURETHRAL SURGERY COMBINED WITH CONCURRENT CISPLATIN, 5-FLUOROURACIL AND TWICE DAILY RADIATION FOLLOWED BY SELECTIVE BLADDER PRESERVATION IN OPERABLE PATIENTS WITH MUSCLE INVADING BLADDER CANCERJournal of Urology, 1998
- Prognostic factors in muscle‐invasive bladder cancer treated with radiotherapy: an immunohistochemical studyBritish Journal of Urology, 1998
- Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancerInternational Journal of Radiation Oncology*Biology*Physics, 1996
- Hyperfractionated Radiotherapy of Bladder Cancer: A ten-year follow-up of a randomized clinical trialActa Oncologica, 1994
- Radical Radiation Treatment of Invasive and Locally Advanced Bladder Carcinoma in Elderly PatientsBritish Journal of Urology, 1991